Halozyme Therapeutics, Inc. (FRA:RV7)

Germany · Delayed Price · Currency is EUR

59.82

+2.68 (4.69%)

At close: Jan 5, 2026

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
United States Revenue	-	690.46M	Log In	Log In	Log In	Upgrade
Switzerland Revenue	-	212.39M	Log In	Log In	Log In	Upgrade
Belgium Revenue	-	84.01M	Log In	Log In	Log In	Upgrade
Japan Revenue	-	18.94M	Log In	Log In	Log In	Upgrade
Ireland Revenue	-	-	Log In	Log In	Log In	Upgrade
All Other Foreign Countries Revenue (Pre-FY2023)	-	-	Log In	Log In	Log In	Upgrade
All Other Foreign Countries Revenue (Post-FY2022)	-	9.53M	Log In	Log In	Log In	Upgrade
Revenue (Total)	1.24B	1.02B	Log In	Log In	Log In	Upgrade

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
Royalties Revenue	780.29M	570.99M	Log In	Log In	Log In	Upgrade
Sales of Proprietary Products	182.34M	166.62M	Log In	Log In	Log In	Upgrade
Sales of Bulk rHuPH20	102.48M	86.33M	Log In	Log In	Log In	Upgrade
Sales of Device Partnered Products	48.32M	50.54M	Log In	Log In	Log In	Upgrade
Total Net Product Sales	333.14M	303.49M	Log In	Log In	Log In	Upgrade
Revenue Under Collaborative Agreements	129.42M	140.84M	Log In	Log In	Log In	Upgrade
Revenue (Total)	1.24B	1.02B	Log In	Log In	Log In	Upgrade

Updated Sep 30, 2025. Data Source: Fiscal.ai.